There is a growing need to shift from 'reactive' management driven by disease complications to 'proactive' care with the aim to prevent disease damages.8
Precision medicine is based on the classification of individuals into subpopulations according to clinical and molecular characteristics, to tailor preventative and therapeutic interventions to the characteristics of each patient.
Interventions would thus be performed only on those who will benefit, sparing side effects and expenses for those who will not.9
Clinical factors, biomarkers and tools are therefore necessary to allow selection of the right drug, at the right time to the right patient.8,9
What is VDZ-CDST and how has it been validated?
Discover the KOL’s discussion on VDZ-CDST
Calculate the VDZ-CDST score via the web calculator for your patients
*Further studies are needed to determine how the VDZ-CDST scoring system in CD can be used for SC vedolizumab. CD, Crohn’s disease; CDST, clinical decision support tool; HRU, healthcare resource utilisation; IBD, inflammatory bowel disease; LTS, long-term safety; PRO, patient-reported outcome; QoL, quality of life; SC, subcutaneous; UST, ustekinumab; VDZ, vedolizumab. 1. Dulai PS, et al. Gastroenterology 2018;155:687–695; 2. Dulai PS, et al. J Crohns Colitis 2021;195–202; 3. Alric H, et al. Inflamm Bowel Dis 2022;28:218–225; 4. Dulai PS, et al. Crohns Colitis 360,XXXX,4,1-8; 5. Chalakatevaki K, et al. United Eur Gastroenterol J 2022;10(8 suppl):797–798; 6. Dulai PS, et al. J Crohns Colitis 2023;17(1 suppl):i490–i491; 7. Dulai PS, et al. Am J Gastroenterol 118(10S):p S670 – S671, October 2023; 8. Borg-Bartolo SP, et al. F1000Res 2020; 9: 54; 9. Vieujean S, et al. Therap Adv Gastroenterol. 2023, Vol.16: 1-52.
C-APROM/BE/ENTY/0261 - Aug 2024